T-2 A morphometric and immunohistochemical study to assess the benefit of an SVR in HCV cirrhotic patients
Roberta D apos Ambrosio, Pierre Bédossa(Régie Autonome des Transports Parisiens (France)), Valérie Paradis(Inserm), Alessio Aghemo, Maria Grazia Rumi(University of Milan), G. Ronchi(University of Milan), M. Colombo(University of Milan), Maria Francesca Donato(University of Milan)
Cited by 6
Related Papers
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661